Pearson J M, Schultze A E, Jean P A, Roth R A
Department of Pharmacology, Michigan State University East Lansing.
Shock. 1995 Sep;4(3):178-86. doi: 10.1097/00024382-199509000-00005.
Intravenous administration of lipopolysaccharide (LPS) to rats results in multifocal, primarily midzonal hepatic necrosis. The hepatic injury is associated with inflammation and is dependent on neutrophils and the coagulation system. After LPS injection into rats, plasma fibrinogen concentration and numbers of blood platelets and leukocytes decrease. Results of our studies, using immunocytochemistry for the detection of neutrophils and 111indium-labeling to identify platelets, indicate that both neutrophils and platelets accumulate within the liver early after administration of LPS to rats. The accumulation of platelets in the liver before the onset of injury suggested that platelets contribute to the manifestation of LPS-induced hepatotoxicity. To test this hypothesis, the number of circulating blood platelets was decreased by the administration of an anti-rat platelet serum (APS) before LPS administration. The consequent thrombocytopenia by APS administration was associated with an attenuation of both LPS-induced liver injury and the activation of the coagulation system. However, the APS treatment did not prevent the hepatic neutrophil accumulation. These results suggest that platelets contribute to the pathogenesis of liver injury after LPS administration, perhaps through their integral role in coagulation and/or interaction with neutrophils, but they do not appear to contribute to hepatic neutrophil accumulation.
给大鼠静脉注射脂多糖(LPS)会导致多灶性肝坏死,主要位于肝中区。肝损伤与炎症相关,且依赖于中性粒细胞和凝血系统。给大鼠注射LPS后,血浆纤维蛋白原浓度、血小板和白细胞数量会减少。我们利用免疫细胞化学检测中性粒细胞和用铟-111标记鉴定血小板的研究结果表明,给大鼠注射LPS后早期,中性粒细胞和血小板都会在肝脏内积聚。在损伤发生前血小板在肝脏内的积聚表明,血小板在LPS诱导的肝毒性表现中起作用。为了验证这一假设,在给予LPS之前,通过注射抗大鼠血小板血清(APS)来减少循环血中的血小板数量。APS给药导致的血小板减少与LPS诱导的肝损伤及凝血系统激活的减弱相关。然而,APS治疗并未阻止肝脏中中性粒细胞的积聚。这些结果表明,血小板可能通过在凝血中的重要作用和/或与中性粒细胞的相互作用,在LPS给药后肝损伤的发病机制中起作用,但它们似乎对肝脏中中性粒细胞的积聚没有影响。